Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[A case report:the progress of fascioliasis from hepatic phase to biliary phase].
Okano F, Harusato A, Tokuda B, Taketani H, Ishiba H, Fukui A, Omatsu T, Okayama T, Satoh O, Imura T, Okita M, Katada K, Itoh Y. Okano F, et al. Among authors: ishiba h. Nihon Shokakibyo Gakkai Zasshi. 2023;120(3):269-275. doi: 10.11405/nisshoshi.120.269. Nihon Shokakibyo Gakkai Zasshi. 2023. PMID: 36908146 Japanese.
Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice.
Yamaguchi K, Nishimura T, Ishiba H, Seko Y, Okajima A, Fujii H, Tochiki N, Umemura A, Moriguchi M, Sumida Y, Mitsuyoshi H, Yasui K, Minami M, Okanoue T, Itoh Y. Yamaguchi K, et al. Among authors: ishiba h. Liver Int. 2015 Feb;35(2):550-61. doi: 10.1111/liv.12645. Epub 2014 Aug 12. Liver Int. 2015. PMID: 25066281
Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease.
Mitsuyoshi H, Yasui K, Hara T, Taketani H, Ishiba H, Okajima A, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Minami M, Itoh Y. Mitsuyoshi H, et al. Among authors: ishiba h. Hepatol Res. 2017 Dec;47(13):1459-1468. doi: 10.1111/hepr.12883. Epub 2017 Mar 29. Hepatol Res. 2017. PMID: 28245087
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H, Fujii H, Shima T, Mitsumoto Y, Ishiba H, Takashima H, Nagao Y, Jo M, Arai M, Hara T, Okajima A, Muramatsu A, Morita A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Itoh Y. Takahashi A, et al. Among authors: ishiba h. Anticancer Res. 2019 Sep;39(9):5149-5156. doi: 10.21873/anticanres.13710. Anticancer Res. 2019. PMID: 31519627
Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K, Yamaguchi K, Seko Y, Okishio S, Ishiba H, Tochiki N, Takahashi A, Kataoka S, Okuda K, Liu Y, Fujii H, Umemura A, Moriguchi M, Okanoue T, Itoh Y. Yano K, et al. Among authors: ishiba h. Lab Invest. 2022 Mar;102(3):281-289. doi: 10.1038/s41374-021-00680-9. Epub 2021 Nov 3. Lab Invest. 2022. PMID: 34732847 Free article.
Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: ishiba h. Hepatol Res. 2017 Oct;47(11):1083-1092. doi: 10.1111/hepr.12840. Epub 2016 Dec 15. Hepatol Res. 2017. PMID: 27862719
Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: ishiba h. Hepatol Res. 2017 Oct;47(11):1206-1211. doi: 10.1111/hepr.12837. Epub 2016 Dec 5. Hepatol Res. 2017. PMID: 27917557
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: ishiba h. Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834. Epub 2016 Dec 7. Hepatol Res. 2017. PMID: 27925353
28 results